AI assistant
MetaVia Inc. — Director's Dealing 2016
Aug 5, 2016
34919_dirs_2016-08-04_5e8eaa3a-7b08-4c3c-a7fe-1092e2f4b75e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-04
Reporting Person: LICHTINGER PEDRO (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $3.556 | 2025-11-24 | Common Stock (32062) | Direct | |
| 8% Convertible Subordinated Promissory Note | $6.7059 | Common Stock () | Direct |
Footnotes
F1: The options were granted on November 25, 2015, and vest in 24 equal monthly increments on the last day of each month, beginning December 1, 2015.
F2: The note was issued in the original principal amount of $250,000. The outstanding principal and accrued interest on such note will automatically convert into shares of common stock, par value $0.001 per share, of Gemphire Therapeutics Inc. (the "Company") immediately prior to the closing of the Company's initial public offering. The note bears interest at a rate of 8% per annum. The note has accrued interest of $13,041 to date and will continue to accrue interest until conversion.